In contrast, IRF8 specifically mediates Aβ-dependent microglial activation via the TREM2-JAK2/STAT1 axis, highlighting its potential as a unique therapeutic target for AD associated with TREM2 mutations [57,58]. This evidence concerns the gene TREM2 and Alzheimer disease.